Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study

UPMC Health System, UPMC Hillman Cancer Center, Dana-Farber Cancer Institute, Institut Gustave Roussy, National Cancer Center Hospital East, Budgetary Health Care Institution of the Omsk Region "Clinical Oncology Center", Iuliu Hațieganu University of Medicine and Pharmacy, Institute of Oncology Prof. Dr. Ion Chiricuta, KU Leuven, Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia, City Clinical Oncology Center, Centre Hospitalier Universitaire de Bordeaux, Hospital Universitari i Politècnic La Fe, Seoul National University Hospital, Sumy State University, Centre Jean Bernard, Clinique Victor Hugo, AstraZeneca (United States), AstraZeneca (United Kingdom), Centre Léon Bérard, University of Milan, Fondazione IRCCS Istituto Nazionale dei Tumori